

Resource Summary Report

Generated by [ASWG](#) on Aug 9, 2026

Anti-Human CD28 (CD28.2)-160Gd

RRID:AB_2868400

Type: Antibody

Proper Citation

(Standard BioTools Cat# 3160003, RRID:AB_2868400)

Antibody Information

URL: http://antibodyregistry.org/AB_2868400

Proper Citation: (Standard BioTools Cat# 3160003, RRID:AB_2868400)

Target Antigen: CD28

Clonality: monoclonal

Comments: Applications: Mass cytometry

Antibody Name: Anti-Human CD28 (CD28.2)-160Gd

Description: This monoclonal targets CD28

Target Organism: human

Clone ID: CD28.2

Antibody ID: AB_2868400

Vendor: Standard BioTools

Catalog Number: 3160003

Record Creation Time: 20260130T082123+0000

Record Last Update: 20260225T232050+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD28 (CD28.2)-160Gd.

No alerts have been found for Anti-Human CD28 (CD28.2)-160Gd.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Ma T, et al. (2026) Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV rebound. *Immunity*, 59(5), 1454.

Gheitasi R, et al. (2025) Age- and sex-associated differences in immune cell populations. *iScience*, 28(8), 113092.

Gao H, et al. (2025) BACH2 promotes seeding and establishment of long-lived HIV-1 reservoir in memory CD4+ T cells. *Cell reports. Medicine*, 6(9), 102311.

Christenson ES, et al. (2025) Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3182.

Tang M, et al. (2025) Single cell immune profiling in ankylosing spondylitis reveals resistance of CD8+ T cells to immune exhaustion. *iScience*, 28(7), 112715.

Sjögren T, et al. (2024) Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1. *iScience*, 27(4), 109610.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. *Cell reports. Medicine*, 5(6), 101572.

Rao M, et al. (2023) High-dimensional profiling of pediatric immune responses to solid organ transplantation. *Cell reports. Medicine*, 4(8), 101147.

Sponaule A, et al. (2023) Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. *Cell reports. Medicine*, 4(11), 101268.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Jeger-Madiot R, et al. (2022) Naive and memory CD4+ T cell subsets can contribute to the generation of human Tfh cells. *iScience*, 25(1), 103566.

Esaulova E, et al. (2021) The immune landscape in tuberculosis reveals populations linked to disease and latency. *Cell host & microbe*, 29(2), 165.

Ask EH, et al. (2021) A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. *Med (New York, N.Y.)*, 2(2), 180.

Xie G, et al. (2021) Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. *Cell reports*, 35(4), 109038.

Liu S, et al. (2021) Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. *Cell reports. Medicine*, 2(10), 100411.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.